广西医学
廣西醫學
엄서의학
Guangxi Medical Journal
2015年
8期
1121-1124
,共4页
哮喘%半胱氨酰白三烯%5-脂氧合酶激活蛋白%白三烯拮抗剂%疗效%儿童
哮喘%半胱氨酰白三烯%5-脂氧閤酶激活蛋白%白三烯拮抗劑%療效%兒童
효천%반광안선백삼희%5-지양합매격활단백%백삼희길항제%료효%인동
Asthma%Cysteinyl leukotrienes%5-lipoxygenase activating protein%Leukotrienes antagonist%Efficacy%Children
目的 探讨哮喘患儿外周血半胱氨酰白三烯( CysLTs)水平及5-脂氧合酶激活蛋白( FLAP) mRNA基因表达水平及其临床意义. 方法 哮喘患儿(5岁及以下)40例,按病情等级划分轻、中、重、危重组,另外选取10名健康儿童作对照组. 哮喘患儿随机分为常规治疗组及白三烯( LTs)拮抗剂干预组,每组20例. 分别于入院24 h内、治疗第10天、3个月、1年、2年抽取外周血测定 CysLTs 水平及 FLAP mRNA/β-action mRNA 的相对数值,并记录患儿病情等级和疗效情况.结果 哮喘患儿的入院时CysLTs水平及FLAP mRNA/β-action mRNA的相对数值均高于对照组(P<0.05),CysLTs水平及FLAP mRNA/β-action mRNA与病情程度呈正相关性(P<0.05). 治疗第10天、3个月、1年及2年,LTs拮抗剂干预组的病情分级均轻于常规治疗组,但差异无统计学意义(P>0.05),疗效均优于常规治疗组(P<0.05);在治疗后各观察时间点,LTs拮抗剂干预组CysLTs水平及FLAP mRNA/β-action mRNA的相对数值均显著低于常规治疗组(P<0.05). 结论 CysLTs及FLAP mRNA水平与哮喘的病情呈正相关性,CysLTs可能成为研究哮喘发病和药物治疗的重要指标;采用LTs拮抗剂联合ICS治疗患儿哮喘具有协同作用,有效控制CysLTs及FLAP mRNA水平.
目的 探討哮喘患兒外週血半胱氨酰白三烯( CysLTs)水平及5-脂氧閤酶激活蛋白( FLAP) mRNA基因錶達水平及其臨床意義. 方法 哮喘患兒(5歲及以下)40例,按病情等級劃分輕、中、重、危重組,另外選取10名健康兒童作對照組. 哮喘患兒隨機分為常規治療組及白三烯( LTs)拮抗劑榦預組,每組20例. 分彆于入院24 h內、治療第10天、3箇月、1年、2年抽取外週血測定 CysLTs 水平及 FLAP mRNA/β-action mRNA 的相對數值,併記錄患兒病情等級和療效情況.結果 哮喘患兒的入院時CysLTs水平及FLAP mRNA/β-action mRNA的相對數值均高于對照組(P<0.05),CysLTs水平及FLAP mRNA/β-action mRNA與病情程度呈正相關性(P<0.05). 治療第10天、3箇月、1年及2年,LTs拮抗劑榦預組的病情分級均輕于常規治療組,但差異無統計學意義(P>0.05),療效均優于常規治療組(P<0.05);在治療後各觀察時間點,LTs拮抗劑榦預組CysLTs水平及FLAP mRNA/β-action mRNA的相對數值均顯著低于常規治療組(P<0.05). 結論 CysLTs及FLAP mRNA水平與哮喘的病情呈正相關性,CysLTs可能成為研究哮喘髮病和藥物治療的重要指標;採用LTs拮抗劑聯閤ICS治療患兒哮喘具有協同作用,有效控製CysLTs及FLAP mRNA水平.
목적 탐토효천환인외주혈반광안선백삼희( CysLTs)수평급5-지양합매격활단백( FLAP) mRNA기인표체수평급기림상의의. 방법 효천환인(5세급이하)40례,안병정등급화분경、중、중、위중조,령외선취10명건강인동작대조조. 효천환인수궤분위상규치료조급백삼희( LTs)길항제간예조,매조20례. 분별우입원24 h내、치료제10천、3개월、1년、2년추취외주혈측정 CysLTs 수평급 FLAP mRNA/β-action mRNA 적상대수치,병기록환인병정등급화료효정황.결과 효천환인적입원시CysLTs수평급FLAP mRNA/β-action mRNA적상대수치균고우대조조(P<0.05),CysLTs수평급FLAP mRNA/β-action mRNA여병정정도정정상관성(P<0.05). 치료제10천、3개월、1년급2년,LTs길항제간예조적병정분급균경우상규치료조,단차이무통계학의의(P>0.05),료효균우우상규치료조(P<0.05);재치료후각관찰시간점,LTs길항제간예조CysLTs수평급FLAP mRNA/β-action mRNA적상대수치균현저저우상규치료조(P<0.05). 결론 CysLTs급FLAP mRNA수평여효천적병정정정상관성,CysLTs가능성위연구효천발병화약물치료적중요지표;채용LTs길항제연합ICS치료환인효천구유협동작용,유효공제CysLTs급FLAP mRNA수평.
Objective To investigate the peripheral blood levels of cysteinyl leukotrienes(CysLTs) and 5-lipoxygenase activating protein(FLAP) mRNA in children with asthma and their clinical significance.Methods Forty children(aged 5 years or younger) with asthma were divided into mild, moderate, severe and critical groups according to the severity of asthma.And 10 healthy children were selected as control group.All children with asthma were randomly divided into conventional treatment group(n=20) and leukotrienes(LTs) antagonist group( n=20) .The peripheral blood samples were collected within 24 hours of admission,10 days,3 months,1 year and 2 years after treatment,respectively,for determining the level of CysLTs and the relative value of FLAP mRNA/β-action mRNA,and the severity of asthma and efficacy were recorded.Results Children with asthma obtained a higher level of CysLTs and higher relative value of FLAP mRNA/β-action mRNA on admission compared to the controls(P<0.05),and the level of CysLTs and the relative value of FLAP mRNA/β-action mRNA positively correlated with the severity of asthma(P<0.05).Ten days,3 months,1 year and 2 years after treatment,the severity of asthma in the LTs antagonist group was milder compared to that in the conventional treatment group,with no significant difference(P>0.05),but the efficacy of LTs antagonist group was superior to that of conventional treatment group(P<0.05).The levels of CysLTs and the relative values of FLAP mRNA/β-action mRNA in the LTs antagonist group were significantly lower than those in the conventional treatment group at all time points after treatment(P<0.05).Conclusion The levels of CysLTs and FLAP mRNA both positively correlate with the severity of asthma,and CysLTs may become an important index for the researches on pathogenic mechanism and medication of asthma.LTs antagonist combined with ICS has a synergistic effect on children with asthma,thus effectively controling the levels of CysLTs and FLAP mRNA.
